questionsmedicales.fr
Préparations pharmaceutiques
Association médicamenteuse
Association médicamenteuse : Questions médicales fréquentes
Diagnostic
5
Interactions médicamenteuses
Diagnostic médical
Tests de laboratoire
Efficacité thérapeutique
Effets indésirables
Symptômes cliniques
Évaluation des risques
Pharmacologie
Logiciels médicaux
Bases de données
Symptômes
5
Symptômes
Effets indésirables
Réaction allergique
Symptômes
Inefficacité thérapeutique
Symptômes cliniques
Surdose médicamenteuse
Symptômes
Effets secondaires
Symptômes cliniques
Prévention
5
Prévention
Interactions médicamenteuses
Conseils médicaux
Pharmacothérapie
Éducation des patients
Risques médicaux
Outils médicaux
Interactions médicamenteuses
Engagement des patients
Pharmacothérapie
Traitements
5
Ajustement des doses
Pharmacothérapie
Traitements
Interactions médicamenteuses
Surveillance médicale
Efficacité thérapeutique
Anticoagulants
Interactions médicamenteuses
Gestion des effets secondaires
Pharmacothérapie
Complications
5
Complications
Réactions allergiques
Gestion des complications
Consultation médicale
Facteurs de risque
Polypharmacie
Prévention
Évaluation médicale
Signes d'alerte
Complications
Facteurs de risque
5
Facteurs de risque
Interactions médicamenteuses
Anticoagulants
Interactions médicamenteuses
Mode de vie
Interactions médicamenteuses
Antécédents médicaux
Interactions médicamenteuses
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Association médicamenteuse : Questions médicales les plus fréquentes",
"headline": "Association médicamenteuse : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Association médicamenteuse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-24",
"dateModified": "2026-04-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Association médicamenteuse"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Préparations pharmaceutiques",
"url": "https://questionsmedicales.fr/mesh/D004364",
"about": {
"@type": "MedicalCondition",
"name": "Préparations pharmaceutiques",
"code": {
"@type": "MedicalCode",
"code": "D004364",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Association d'adapalène et de peroxyde de benzoyle",
"alternateName": "Adapalene, Benzoyl Peroxide Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000068801",
"about": {
"@type": "MedicalCondition",
"name": "Association d'adapalène et de peroxyde de benzoyle",
"code": {
"@type": "MedicalCode",
"code": "D000068801",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.032"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Aminophylline",
"alternateName": "Aminophylline",
"url": "https://questionsmedicales.fr/mesh/D000628",
"about": {
"@type": "MedicalCondition",
"name": "Aminophylline",
"code": {
"@type": "MedicalCode",
"code": "D000628",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.048"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association de bésilate d'amlodipine et d'olmésartan médoxomil",
"alternateName": "Amlodipine Besylate, Olmesartan Medoxomil Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000068558",
"about": {
"@type": "MedicalCondition",
"name": "Association de bésilate d'amlodipine et d'olmésartan médoxomil",
"code": {
"@type": "MedicalCode",
"code": "D000068558",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.063"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association d'amlodipine et de valsartan",
"alternateName": "Amlodipine, Valsartan Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000068838",
"about": {
"@type": "MedicalCondition",
"name": "Association d'amlodipine et de valsartan",
"code": {
"@type": "MedicalCode",
"code": "D000068838",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.094"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association amoxicilline-clavulanate de potassium",
"alternateName": "Amoxicillin-Potassium Clavulanate Combination",
"url": "https://questionsmedicales.fr/mesh/D019980",
"about": {
"@type": "MedicalCondition",
"name": "Association amoxicilline-clavulanate de potassium",
"code": {
"@type": "MedicalCode",
"code": "D019980",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.102"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association d'artéméther et de luméfantrine",
"alternateName": "Artemether, Lumefantrine Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000077611",
"about": {
"@type": "MedicalCondition",
"name": "Association d'artéméther et de luméfantrine",
"code": {
"@type": "MedicalCode",
"code": "D000077611",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.110"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association d'aspirine et de dipyridamole",
"alternateName": "Aspirin, Dipyridamole Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000068342",
"about": {
"@type": "MedicalCondition",
"name": "Association d'aspirine et de dipyridamole",
"code": {
"@type": "MedicalCode",
"code": "D000068342",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.125"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Insulines biphasiques",
"alternateName": "Biphasic Insulins",
"url": "https://questionsmedicales.fr/mesh/D061265",
"about": {
"@type": "MedicalCondition",
"name": "Insulines biphasiques",
"code": {
"@type": "MedicalCode",
"code": "D061265",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.249"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association de tartrate de brimonidine et de maléate de timolol",
"alternateName": "Brimonidine Tartrate, Timolol Maleate Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000068599",
"about": {
"@type": "MedicalCondition",
"name": "Association de tartrate de brimonidine et de maléate de timolol",
"code": {
"@type": "MedicalCode",
"code": "D000068599",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.312"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association de bromure d'ipratropium et de salbutamol",
"alternateName": "Albuterol, Ipratropium Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000068600",
"about": {
"@type": "MedicalCondition",
"name": "Association de bromure d'ipratropium et de salbutamol",
"code": {
"@type": "MedicalCode",
"code": "D000068600",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.344"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association de budésonide et de fumarate de formotérol",
"alternateName": "Budesonide, Formoterol Fumarate Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000069502",
"about": {
"@type": "MedicalCondition",
"name": "Association de budésonide et de fumarate de formotérol",
"code": {
"@type": "MedicalCode",
"code": "D000069502",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.348"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association de buprénorphine et de naloxone",
"alternateName": "Buprenorphine, Naloxone Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000069479",
"about": {
"@type": "MedicalCondition",
"name": "Association de buprénorphine et de naloxone",
"code": {
"@type": "MedicalCode",
"code": "D000069479",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.352"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association d'imipénem et de cilastatine",
"alternateName": "Cilastatin, Imipenem Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000077728",
"about": {
"@type": "MedicalCondition",
"name": "Association d'imipénem et de cilastatine",
"code": {
"@type": "MedicalCode",
"code": "D000077728",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.356"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Thérapies par anticorps combinés",
"alternateName": "Combined Antibody Therapeutics",
"url": "https://questionsmedicales.fr/mesh/D000094523",
"about": {
"@type": "MedicalCondition",
"name": "Thérapies par anticorps combinés",
"code": {
"@type": "MedicalCode",
"code": "D000094523",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.358"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Diménhydrinate",
"alternateName": "Dimenhydrinate",
"url": "https://questionsmedicales.fr/mesh/D004111",
"about": {
"@type": "MedicalCondition",
"name": "Diménhydrinate",
"code": {
"@type": "MedicalCode",
"code": "D004111",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.368"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association d'éfavirenz, d'emtricitabine et de fumarate de ténofovir disoproxil",
"alternateName": "Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000068257",
"about": {
"@type": "MedicalCondition",
"name": "Association d'éfavirenz, d'emtricitabine et de fumarate de ténofovir disoproxil",
"code": {
"@type": "MedicalCode",
"code": "D000068257",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association d'elvitégravir, de cobicistat, d'emtricitabine et de fumarate de ténofovir disoproxil",
"alternateName": "Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000069545",
"about": {
"@type": "MedicalCondition",
"name": "Association d'elvitégravir, de cobicistat, d'emtricitabine et de fumarate de ténofovir disoproxil",
"code": {
"@type": "MedicalCode",
"code": "D000069545",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.391"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association d'emtricitabine, de rilpivirine et de ténofovir",
"alternateName": "Emtricitabine, Rilpivirine, Tenofovir Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000068678",
"about": {
"@type": "MedicalCondition",
"name": "Association d'emtricitabine, de rilpivirine et de ténofovir",
"code": {
"@type": "MedicalCode",
"code": "D000068678",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.407"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association d'emtricitabine et de fumarate de ténofovir disoproxil",
"alternateName": "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000069480",
"about": {
"@type": "MedicalCondition",
"name": "Association d'emtricitabine et de fumarate de ténofovir disoproxil",
"code": {
"@type": "MedicalCode",
"code": "D000069480",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.423"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association d'ézétimibe et de simvastatine",
"alternateName": "Ezetimibe, Simvastatin Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000069499",
"about": {
"@type": "MedicalCondition",
"name": "Association d'ézétimibe et de simvastatine",
"code": {
"@type": "MedicalCode",
"code": "D000069499",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.431"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association de fluticasone et de salmétérol",
"alternateName": "Fluticasone-Salmeterol Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000068297",
"about": {
"@type": "MedicalCondition",
"name": "Association de fluticasone et de salmétérol",
"code": {
"@type": "MedicalCode",
"code": "D000068297",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.438"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association de lidocaïne et de prilocaïne",
"alternateName": "Lidocaine, Prilocaine Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000077442",
"about": {
"@type": "MedicalCondition",
"name": "Association de lidocaïne et de prilocaïne",
"code": {
"@type": "MedicalCode",
"code": "D000077442",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.454"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association de furoate de mométasone et de fumarate de formotérol",
"alternateName": "Mometasone Furoate, Formoterol Fumarate Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000068758",
"about": {
"@type": "MedicalCondition",
"name": "Association de furoate de mométasone et de fumarate de formotérol",
"code": {
"@type": "MedicalCode",
"code": "D000068758",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.469"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Médicaments multi-ingrédients contre le rhume, la grippe et l'allergie",
"alternateName": "Multi-Ingredient Cold, Flu, and Allergy Medications",
"url": "https://questionsmedicales.fr/mesh/D057985",
"about": {
"@type": "MedicalCondition",
"name": "Médicaments multi-ingrédients contre le rhume, la grippe et l'allergie",
"code": {
"@type": "MedicalCode",
"code": "D057985",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association de pipéracilline et de tazobactam",
"alternateName": "Piperacillin, Tazobactam Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000077725",
"about": {
"@type": "MedicalCondition",
"name": "Association de pipéracilline et de tazobactam",
"code": {
"@type": "MedicalCode",
"code": "D000077725",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.625"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association de phosphate de sitagliptine et de chlorhydrate de metformine",
"alternateName": "Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000068899",
"about": {
"@type": "MedicalCondition",
"name": "Association de phosphate de sitagliptine et de chlorhydrate de metformine",
"code": {
"@type": "MedicalCode",
"code": "D000068899",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association de tobramycine et de dexaméthasone",
"alternateName": "Tobramycin, Dexamethasone Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D000078162",
"about": {
"@type": "MedicalCondition",
"name": "Association de tobramycine et de dexaméthasone",
"code": {
"@type": "MedicalCode",
"code": "D000078162",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.813"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Association triméthoprime-sulfaméthoxazole",
"alternateName": "Trimethoprim, Sulfamethoxazole Drug Combination",
"url": "https://questionsmedicales.fr/mesh/D015662",
"about": {
"@type": "MedicalCondition",
"name": "Association triméthoprime-sulfaméthoxazole",
"code": {
"@type": "MedicalCode",
"code": "D015662",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Association médicamenteuse",
"alternateName": "Drug Combinations",
"code": {
"@type": "MedicalCode",
"code": "D004338",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Alina Malyutina",
"url": "https://questionsmedicales.fr/author/Alina%20Malyutina",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland."
}
},
{
"@type": "Person",
"name": "Wenyu Wang",
"url": "https://questionsmedicales.fr/author/Wenyu%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland."
}
},
{
"@type": "Person",
"name": "Alberto Pessia",
"url": "https://questionsmedicales.fr/author/Alberto%20Pessia",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland."
}
},
{
"@type": "Person",
"name": "Jing Tang",
"url": "https://questionsmedicales.fr/author/Jing%20Tang",
"affiliation": {
"@type": "Organization",
"name": "Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland."
}
},
{
"@type": "Person",
"name": "Diane S Aschenbrenner",
"url": "https://questionsmedicales.fr/author/Diane%20S%20Aschenbrenner",
"affiliation": {
"@type": "Organization",
"name": "Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com ."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "New antifungal strategies: Drug combination and co-delivery.",
"datePublished": "2023-05-19",
"url": "https://questionsmedicales.fr/article/37211279",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.addr.2023.114874"
}
},
{
"@type": "ScholarlyArticle",
"name": "An integrated computational strategy to predict personalized cancer drug combinations by reversing drug resistance signatures.",
"datePublished": "2023-07-01",
"url": "https://questionsmedicales.fr/article/37418899",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.compbiomed.2023.107230"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ex vivo discovery of synergistic drug combinations for hematologic malignancies.",
"datePublished": "2023-12-13",
"url": "https://questionsmedicales.fr/article/38101570",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.slasd.2023.12.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Systematic analysis of drug combinations against Gram-positive bacteria.",
"datePublished": "2023-09-28",
"url": "https://questionsmedicales.fr/article/37770760",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41564-023-01486-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Multi-Drug Concentration Gradient Mixing Chip: A Novel Platform for High-Throughput Drug Combination Screening.",
"datePublished": "2024-04-23",
"url": "https://questionsmedicales.fr/article/38785686",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/bios14050212"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Préparations pharmaceutiques",
"item": "https://questionsmedicales.fr/mesh/D004364"
},
{
"@type": "ListItem",
"position": 3,
"name": "Association médicamenteuse",
"item": "https://questionsmedicales.fr/mesh/D004338"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Association médicamenteuse - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Association médicamenteuse",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Association médicamenteuse",
"description": "Comment diagnostiquer une interaction médicamenteuse ?\nQuels tests pour évaluer l'efficacité des associations ?\nQuels signes indiquent une mauvaise association médicamenteuse ?\nComment évaluer le risque d'interactions ?\nQuels outils pour diagnostiquer les associations ?",
"url": "https://questionsmedicales.fr/mesh/D004338#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Association médicamenteuse",
"description": "Quels symptômes d'une interaction médicamenteuse ?\nComment reconnaître une réaction allergique ?\nQuels signes d'inefficacité d'une association ?\nQuels symptômes d'une surdose médicamenteuse ?\nComment différencier effets secondaires et symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D004338#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Association médicamenteuse",
"description": "Comment prévenir les interactions médicamenteuses ?\nQuels conseils pour une bonne prise de médicaments ?\nComment éduquer les patients sur les risques ?\nQuels outils pour prévenir les interactions ?\nComment impliquer les patients dans leur traitement ?",
"url": "https://questionsmedicales.fr/mesh/D004338#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Association médicamenteuse",
"description": "Comment ajuster les doses dans une association ?\nQuels traitements pour éviter les interactions ?\nComment surveiller l'efficacité d'une association ?\nQuels médicaments à éviter en association ?\nComment gérer les effets secondaires d'une association ?",
"url": "https://questionsmedicales.fr/mesh/D004338#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Association médicamenteuse",
"description": "Quelles complications peuvent survenir avec des associations ?\nComment gérer une complication d'association ?\nQuels facteurs augmentent le risque de complications ?\nComment prévenir les complications liées aux associations ?\nQuels signes d'alerte pour des complications ?",
"url": "https://questionsmedicales.fr/mesh/D004338#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Association médicamenteuse",
"description": "Quels facteurs de risque pour les interactions ?\nComment l'âge influence-t-il les associations ?\nQuels médicaments augmentent le risque d'interactions ?\nComment le mode de vie affecte-t-il les interactions ?\nQuels antécédents médicaux sont préoccupants ?",
"url": "https://questionsmedicales.fr/mesh/D004338#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une interaction médicamenteuse ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'interaction est diagnostiquée par l'analyse des antécédents médicaux et des médicaments prescrits."
}
},
{
"@type": "Question",
"name": "Quels tests pour évaluer l'efficacité des associations ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de laboratoire et des évaluations cliniques sont utilisés pour mesurer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une mauvaise association médicamenteuse ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets indésirables, une aggravation des symptômes ou une absence d'amélioration peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Comment évaluer le risque d'interactions ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par l'analyse des profils pharmacologiques des médicaments concernés."
}
},
{
"@type": "Question",
"name": "Quels outils pour diagnostiquer les associations ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des logiciels et bases de données d'interactions médicamenteuses sont utilisés par les professionnels."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une interaction médicamenteuse ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des nausées, des vertiges, des éruptions cutanées ou des douleurs."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une réaction allergique se manifeste par des démangeaisons, un gonflement ou des difficultés respiratoires."
}
},
{
"@type": "Question",
"name": "Quels signes d'inefficacité d'une association ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'inefficacité peut se manifester par la persistance des symptômes malgré le traitement."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une surdose médicamenteuse ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent confusion, somnolence, nausées et troubles de la coordination."
}
},
{
"@type": "Question",
"name": "Comment différencier effets secondaires et symptômes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires sont des réactions indésirables aux médicaments, tandis que les symptômes sont des manifestations de la maladie."
}
},
{
"@type": "Question",
"name": "Comment prévenir les interactions médicamenteuses ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Informer le médecin de tous les médicaments pris et éviter l'automédication aide à prévenir les interactions."
}
},
{
"@type": "Question",
"name": "Quels conseils pour une bonne prise de médicaments ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Suivre les prescriptions, respecter les horaires et ne pas mélanger les médicaments sans avis médical."
}
},
{
"@type": "Question",
"name": "Comment éduquer les patients sur les risques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fournir des informations claires sur les médicaments et leurs interactions lors des consultations."
}
},
{
"@type": "Question",
"name": "Quels outils pour prévenir les interactions ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des applications ou des bases de données d'interactions médicamenteuses pour les professionnels."
}
},
{
"@type": "Question",
"name": "Comment impliquer les patients dans leur traitement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Encourager les patients à poser des questions et à exprimer leurs préoccupations sur leurs traitements."
}
},
{
"@type": "Question",
"name": "Comment ajuster les doses dans une association ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les doses doivent être ajustées en fonction de l'âge, du poids et de la fonction rénale du patient."
}
},
{
"@type": "Question",
"name": "Quels traitements pour éviter les interactions ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des médicaments avec des mécanismes d'action différents peut réduire le risque d'interactions."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité d'une association ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance se fait par des consultations régulières et des tests de suivi pour évaluer les résultats."
}
},
{
"@type": "Question",
"name": "Quels médicaments à éviter en association ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments, comme les anticoagulants et les anti-inflammatoires, peuvent interagir dangereusement."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires d'une association ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est essentiel de signaler tout effet secondaire au médecin pour ajuster le traitement si nécessaire."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des associations ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des réactions allergiques graves, des saignements ou des défaillances organiques."
}
},
{
"@type": "Question",
"name": "Comment gérer une complication d'association ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est crucial d'arrêter le médicament suspect et de consulter un professionnel de santé immédiatement."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les maladies chroniques et la polypharmacie augmentent le risque de complications."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées aux associations ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une évaluation régulière des traitements et une communication ouverte avec le médecin sont essentielles."
}
},
{
"@type": "Question",
"name": "Quels signes d'alerte pour des complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes tels que des douleurs thoraciques, des éruptions cutanées ou des saignements doivent alerter."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque pour les interactions ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, le sexe, les antécédents médicaux et le nombre de médicaments pris."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il les associations ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées sont plus susceptibles de subir des interactions en raison de la polypharmacie."
}
},
{
"@type": "Question",
"name": "Quels médicaments augmentent le risque d'interactions ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les médicaments comme les anticoagulants, les antibiotiques et les anticonvulsivants sont à risque."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie affecte-t-il les interactions ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme, l'alcool et une mauvaise alimentation peuvent influencer l'efficacité des médicaments."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux sont préoccupants ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies hépatiques ou rénales augmentent le risque d'interactions médicamenteuses."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 15/04/2026
Contenu vérifié selon les dernières recommandations médicales
└─
Association d'adapalène et de peroxyde de benzoyle
Adapalene, Benzoyl Peroxide Drug Combination
D000068801 -
D26.310.032
└─
Aminophylline
Aminophylline
D000628 -
D26.310.048
└─
Association de bésilate d'amlodipine et d'olmésartan médoxomil
Amlodipine Besylate, Olmesartan Medoxomil Drug Combination
D000068558 -
D26.310.063
└─
Association d'amlodipine et de valsartan
Amlodipine, Valsartan Drug Combination
D000068838 -
D26.310.094
└─
Association amoxicilline-clavulanate de potassium
Amoxicillin-Potassium Clavulanate Combination
D019980 -
D26.310.102
└─
Association d'artéméther et de luméfantrine
Artemether, Lumefantrine Drug Combination
D000077611 -
D26.310.110
└─
Association d'aspirine et de dipyridamole
Aspirin, Dipyridamole Drug Combination
D000068342 -
D26.310.125
└─
Insulines biphasiques
Biphasic Insulins
D061265 -
D26.310.249
└─
Association de tartrate de brimonidine et de maléate de timolol
Brimonidine Tartrate, Timolol Maleate Drug Combination
D000068599 -
D26.310.312
└─
Association de bromure d'ipratropium et de salbutamol
Albuterol, Ipratropium Drug Combination
D000068600 -
D26.310.344
└─
Association de budésonide et de fumarate de formotérol
Budesonide, Formoterol Fumarate Drug Combination
D000069502 -
D26.310.348
└─
Association de buprénorphine et de naloxone
Buprenorphine, Naloxone Drug Combination
D000069479 -
D26.310.352
└─
Association d'imipénem et de cilastatine
Cilastatin, Imipenem Drug Combination
D000077728 -
D26.310.356
└─
Thérapies par anticorps combinés
Combined Antibody Therapeutics
D000094523 -
D26.310.358
└─
Diménhydrinate
Dimenhydrinate
D004111 -
D26.310.368
└─
Association d'éfavirenz, d'emtricitabine et de fumarate de ténofovir disoproxil
Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
D000068257 -
D26.310.375
└─
Association d'elvitégravir, de cobicistat, d'emtricitabine et de fumarate de ténofovir disoproxil
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
D000069545 -
D26.310.391
└─
Association d'emtricitabine, de rilpivirine et de ténofovir
Emtricitabine, Rilpivirine, Tenofovir Drug Combination
D000068678 -
D26.310.407
└─
Association d'emtricitabine et de fumarate de ténofovir disoproxil
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
D000069480 -
D26.310.423
└─
Association d'ézétimibe et de simvastatine
Ezetimibe, Simvastatin Drug Combination
D000069499 -
D26.310.431
└─
Association de fluticasone et de salmétérol
Fluticasone-Salmeterol Drug Combination
D000068297 -
D26.310.438
└─
Association de lidocaïne et de prilocaïne
Lidocaine, Prilocaine Drug Combination
D000077442 -
D26.310.454
└─
Association de furoate de mométasone et de fumarate de formotérol
Mometasone Furoate, Formoterol Fumarate Drug Combination
D000068758 -
D26.310.469
└─
Médicaments multi-ingrédients contre le rhume, la grippe et l'allergie
Multi-Ingredient Cold, Flu, and Allergy Medications
D057985 -
D26.310.500
└─
Association de pipéracilline et de tazobactam
Piperacillin, Tazobactam Drug Combination
D000077725 -
D26.310.625
└─
Association de phosphate de sitagliptine et de chlorhydrate de metformine
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
D000068899 -
D26.310.750
└─
Association de tobramycine et de dexaméthasone
Tobramycin, Dexamethasone Drug Combination
D000078162 -
D26.310.813
└─
Association triméthoprime-sulfaméthoxazole
Trimethoprim, Sulfamethoxazole Drug Combination
D015662 -
D26.310.875
2 publications dans cette catégorie
Affiliations :
Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Publications dans "Association médicamenteuse" :
2 publications dans cette catégorie
Affiliations :
Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Publications dans "Association médicamenteuse" :
2 publications dans cette catégorie
Affiliations :
Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Publications dans "Association médicamenteuse" :
2 publications dans cette catégorie
Affiliations :
Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Publications dans "Association médicamenteuse" :
2 publications dans cette catégorie
Affiliations :
Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .
Publications dans "Association médicamenteuse" :
2 publications dans cette catégorie
Affiliations :
Icosagen Cell Factory OÜ, 61713 Kambja vald Tartumaa, Estonia.
Publications dans "Association médicamenteuse" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
Publications dans "Association médicamenteuse" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
Institute of Technology, University of Tartu, 50090 Tartu, Estonia.
Institute for Molecular Medicine Finland, FIMM, University of Helsinki, 00014 Helsinki, Finland.
Publications dans "Association médicamenteuse" :
2 publications dans cette catégorie
Affiliations :
Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Avenue Mounier, 73, B1 73.12, 1200 Brussels, Belgium.
Publications dans "Association médicamenteuse" :
2 publications dans cette catégorie
Affiliations :
Department of Radiation Oncology, Wentworth Douglass Hospital and Seacoast Cancer Center, Dover, New Hampshire. r.atkin@ucl.ac.uk a.june.walker@gmail.com.
Publications dans "Association médicamenteuse" :
1 publication dans cette catégorie
Affiliations :
Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Publications dans "Association médicamenteuse" :
1 publication dans cette catégorie
Affiliations :
Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
Publications dans "Association médicamenteuse" :
1 publication dans cette catégorie
Affiliations :
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia. Electronic address: Philip.thompson@monash.edu.
Publications dans "Association médicamenteuse" :
1 publication dans cette catégorie
Affiliations :
Blood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Victoria 3168, Australia; Monash Hematology, Monash Health, Melbourne, Victoria 3168, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria 3000, Australia.
Publications dans "Association médicamenteuse" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania 15216, United States.
Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, The University of Pittsburgh, 3501 Terrace Street, Pittsburgh, Pennsylvania 15261, United States.
Publications dans "Association médicamenteuse" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, The University of Pittsburgh, 3501 Terrace Street, Pittsburgh, Pennsylvania 15261, United States.
NIH National Center of Excellence for Computational Drug Abuse Research, The University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.
Publications dans "Association médicamenteuse" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, The University of Pittsburgh, 3501 Terrace Street, Pittsburgh, Pennsylvania 15261, United States.
NIH National Center of Excellence for Computational Drug Abuse Research, The University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.
Publications dans "Association médicamenteuse" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, The University of Pittsburgh, 3501 Terrace Street, Pittsburgh, Pennsylvania 15261, United States.
NIH National Center of Excellence for Computational Drug Abuse Research, The University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.
Publications dans "Association médicamenteuse" :
1 publication dans cette catégorie
Affiliations :
Computational and Systems Biology, Drug Discovery Institute, The University of Pittsburgh, 800 Murdoch Building, 3420 Forbes Avenue, Pittsburgh, Pennsylvania 15260, United States.
Publications dans "Association médicamenteuse" :
1 publication dans cette catégorie
Affiliations :
Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, The University of Pittsburgh, 3501 Terrace Street, Pittsburgh, Pennsylvania 15261, United States.
NIH National Center of Excellence for Computational Drug Abuse Research, The University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.
Publications dans "Association médicamenteuse" :
The growing occurrence of invasive fungal infections and the mounting rates of drug resistance constitute a significant menace to human health. Antifungal drug combinations have garnered substantial i...
Drug resistance currently poses the greatest barrier to cancer treatments. To overcome drug resistance, drug combination therapy has been proposed as a promising treatment strategy. Herein, we present...
Combination therapies have improved outcomes for patients with acute myeloid leukemia (AML). However, these patients still have poor overall survival. Although many combination therapies are identifie...
Drug combinations can expand options for antibacterial therapies but have not been systematically tested in Gram-positive species. We profiled ~8,000 combinations of 65 antibacterial drugs against the...
Combinatorial drug therapy has emerged as a critically important strategy in medical research and patient treatment and involves the use of multiple drugs in concert to achieve a synergistic effect. T...
In its 'Road map for neglected tropical diseases 2021-2030', the World Health Organization outlined its targets for control and elimination of neglected tropical diseases (NTDs) and research needed to...
Combination therapy is a promising clinical treatment strategy for cancer and other complex diseases. Multiple drugs can target multiple proteins and pathways, greatly improving the therapeutic effect...
Drug combination therapy has become a common strategy for the treatment of complex diseases. There is an urgent need for computational methods to efficiently identify appropriate drug combinations owi...
The discovery of anticancer drug combinations is a crucial work of anticancer treatment. In recent years, pre-screening drug combinations with synergistic effects in a large-scale search space adoptin...
In this paper, we propose MTLSynergy which is based on multi-task learning and deep neural networks to predict synergistic anticancer drug combinations. It simultaneously learns two crucial prediction...
Compared with the previous methods listed in this paper, MTLSynergy achieves the lowest mean square error of 216.47 and the highest Pearson correlation coefficient of 0.76 on the drug synergy predicti...
Our study suggests that multi-task learning is significantly beneficial for both drug synergy prediction and monotherapy sensitivity prediction when combining these two tasks into one model. The abili...
Combination of anti-cancer drugs is broadly seen as way to overcome the often-limited efficacy of single agents. The design and testing of combinations are however very challenging. Here we present a ...